A Phase 2 interventional study of tDCS and tSCS in Stroke, Spinal Cord Injury and Able Bodied, sponsored by Centre National de la Recherche Scientifique, France. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Centre National de la Recherche Scientifique, France · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 545 studies in Stroke with a site in France — 142 open to participants now, 161 under way, 12 of them phase 3. Stroke · France.
Among the 545 studies in Stroke with a site in France, this one is the 218th largest by planned enrollment of the 370 interventional ones that give a count, is one of 32 that started in 2024, is one of 18 in phase 2, reaches primary completion later than 81 of the 160 other live ones, and was the 509th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →142 of the 545 studies in Stroke with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–80
University Hospital, Bordeaux · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 52 · Phase 4 17
First in 1998; this study’s year is marked. 32 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is close to the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 64 across the 370 interventional studies, 180 across the 173 observational. Of the 332 that completed or were terminated, 30 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 545 have an industry lead sponsor. The 10 most frequent:
Centre National de la Recherche Scientifique, France is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Centre National de la Recherche Scientifique, France has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
48 of the studies in Stroke with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03998852Phase 3University Hospital, BordeauxIn Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. | 2027-04-13 |
| NCT06059144Phase 3University Hospital, BordeauxInduced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine | 2027-08-28 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT00759304Centre Hospitalier Universitaire de Saint EtienneEvaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events | 2026-12 |
Add all 48 to your calendar (.ics) → With an account.
Among the 545 studies in Stroke with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to investigate the potential synergy between non-invasive brain and spinal cord stimulation administered during a cognitive-motor task, in terms of their immediate effects on sensorimotor and cognitive functions after neurological injuries affecting the upper limb (cervical spinal cord injury and stroke). Secondary objectives are to evaluate the relevance of anatomical MRI, functional MRI, and neurophysiological measurements for optimizing and predicting the effects of these different interventions.
Over the past decade, innovative electrical stimulation strategies have emerged to improve the effectiveness of conventional rehabilitation approaches following spinal cord injury or stroke. Transcranial direct current stimulation (tDCS) and transcutaneous spinal cord stimulation (tSCS) are two non-invasive stimulation techniques targeting respectively the brain and spinal cord. These techniques have demonstrated immediate and lasting positive effects on the recovery of lost neurological functions following damage to the brain (in the case of stroke) or the spinal cord (in the case of spinal cord injury). Functional improvements leading to a better quality of life have been demonstrated in response to tSCS or tDCS sessions combined with motor training. Recent studies suggest a potential synergistic effect of these two types of intervention, which we propose to characterize in control participants, participants with cervical spinal cord injury, and post-stroke participants.
OBJECTIVES: In this project, we seek to study the potential synergistic effects of an intervention combining non-invasive stimulation of the brain and spinal cord, administered during the performance of a cognitive-motor task, compared to a control intervention and each intervention administered separately, on the recovery of motor and cognitive-motor functions after neurological injury. Secondary objectives are to evaluate the relevance of anatomical MRI data and neurophysiological measurements for optimizing and predicting the effects of these different interventions.
METHODOLOGY/RESEARCH DESIGN: Single-center, prospective, comparative, randomized, crossover, and single-blind clinical study comparing four neuromodulation interventions: S1: tDCS, S2: tSCS, S3: tDCS-tSCS, S4: sham, administered during a cognitive-motor training task of the affected upper limb using the Armeo technology. Three groups of participants will be included: one control group, one group with cervical spinal cord injury, and one post-stroke group. The two groups with either spinal cord injury or stroke will participate in a total of nine visits: the inclusion visit, four testing visits, and four intervention visits. The control group will participate only in the inclusion and testing visits. Outcome measures will include neurophysiological and clinical performance measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
CONTROL GROUP:
POST-STROKE GROUP:
SCI GROUP:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tDCS administered during the performance of cognitive and motor task for 20 min
Procedure: tDCS · Behavioral: Cognitive-Motor Task
20-min tSCS administered during the performance of cognitive and motor task for 20 min
Procedure: tSCS · Procedure: Sham
tDCS associated with tSCS administered during the performance of cognitive and motor task for 20 min
Procedure: tDCS · Procedure: tSCS · Behavioral: Cognitive-Motor Task
Sham tDCS associated with Sham tSCS administered during the performance of cognitive and motor task for 20 min
Procedure: tDCS · Procedure: tSCS · Procedure: Sham · Behavioral: Cognitive-Motor Task
tDCS will be delivered using an electrical stimulation device d (1X1 tES, Soterix Medical Inc., USA, CE marked) delivering a direct current at 2 mA for a period of 20 minutes. Silicone electrodes are placed in sponges soaked in physiological saline (5 cm × 7 cm) (EASYpadTM, Soterix Medical Inc.), with the anode and cathode centered on the optimal cortical areas determined during testing visits.
Also known as: transcranial Direct Current Stimulation
tSCS will be applied for 20 minutes using a constant current electrical stimulator (DS5 or DS7A, Digitimer Ltd, CE marked) delivering monophasic pulses at 30 Hz at stimulation sites and intensities specific to each participant and defined in advance during testing visits.
Also known as: transcutaneous Spinal Cord Stimulation
For the sham stimulation interventions, the current slowly increases to the intensity used during the active interventions for 30 seconds, then slowly decreases over the next 30 seconds, at the beginning and end of the stimulation. The sham interventions use the same electrode placements as during the active ones for a total duration of 20 min.
The cognitive-motor task will be administered using the ArmeoControl software supplied with the ArmeoSping® or ArmeoPower® upper limb rehabilitation exoskeleton. Participants will be seated in a chair or their wheelchair and fitted into the exoskeleton.The exoskeleton is linked to a series of exercises performed on a computer via a virtual reality interface (ArmeoControl), which allows simultaneous training of the arms and hands in a large workspace. Two vertical and horizontal "visually guided reaching" tasks will be offered, each lasting 10 minutes. These tasks are chosen to provide training in cognitive-motor functions (grabbing a target moving in a virtual workspace) and sensorimotor functions (interacting with the exoskeleton to move the target).
Sensory Performance
GRASSP subscores: Hand dorsal and palmar sensory function
Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)
Quantitative Prehension Performance
GRASSP Quantitative Prehension Subscore: Hand prehension motor performance
Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)
Cognitive performance
Total score on the ECAS multi-domain assessment
Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)
Safety of the intervention
Safety questionnaire describing side effect appearance and their relative severity. The frequency of a specific side effect will be computed and the severity score (1 to 4) will be averaged across participant
Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)
Feasibility of the intervention
4-item instrument measuring the feasibility of an intervention. The total score is calculated by summing the four items, yielding a range from 4 to 20, with higher scores indicating greater perceived feasibility of the intervention.
Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)
Neurophysiological assessment of posterior root-muscle reflexes
Upper-limb electromyographic (EMG) responses during paired-pulse tSCS
Time frame: Immediately post-intervention at testing visit #2 (day 4)
Plan to share: Undecided — Based on request and on the data type requested and ethically approved (only non-personally Identifiable Information).
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.
Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 31 months is below that.
Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre National de la Recherche Scientifique, France